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Abstract 
 
The CD20-targeting monoclonal antibody Rituximab is an established component of 
immunochemotherapeutic regimens against B-cell lymphomas, where its co-administration 
with conventional anti-cancer agents has significantly improved long-term outcome. 
However, the cellular mechanisms by which Rituximab exerts its anti-lymphoma activity are 
only partially understood. We show here that Rituximab induces typical features of cellular 
senescence, a long-term growth arrest of viable cells with distinct biological properties, in 
established B-cell lymphoma cell lines as well as primary transformed B-cells. In addition, 
Rituximab-based immunotherapy sensitized lymphoma cells to senescence induction by the 
chemotherapeutic compound Adriamycin (a.k.a. Doxorubicin), and, to a lesser extent, by the 
antimicrotubule agent Vincristine. Anti-CD20 treatment further enhanced secretion of 
senescence-associated cytokines, and augmented the DNA damage response (DDR) 
signaling cascade triggered by Adriamycin. As the underlying pro-senescence mechanism, 
we found intracellular reactive oxygen species (ROS) levels to be elevated  in response to 
Rituximab, and, in turn, the ROS scavenger N-acetylcysteine (NAC) to largely abrogate 
Rituximab-mediated senescence. Our results, further supported by gene set enrichment 
analyses in a clinical data set of chronic lymphocytic leukemia patient samples exposed to a 
Rituximab-containing treatment regimen, provide important mechanistic insights into the 
biological complexity of anti-CD20-evoked tumor responses, and unveil cellular senescence 
as a hitherto unrecognized effector principle of the antibody component in lymphoma 
immunochemotherapy. 
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Introduction 
 
The modes of action by which the CD20-targeting antibody Rituximab (RTX) produces 
clinical benefits in aggressive and indolent lymphoma are complex and have not been fully 
elucidated (1-3). It is well established that CD20-bound RTX recruits host immune effector 
principles such as antibody-dependent cellular cytotoxicity (ADCC) and complement-
mediated cytolysis via its Fc domain (4-7). Moreover, RTX has been shown to slow 
proliferation and to induce apoptosis when tested against lymphoma cell lines in short-term 
assays (8), thereby contributing to the anti-tumor activity of conventional chemotherapeutic 
agents (3,9,10). However, in contrast to a lysosome-mediated cell death pathway that is 
triggered by so called type II CD20 antibodies, more recent studies reported only limited 
lymphoma cell death by the type I antibody Rituximab (11). Interestingly, although the 
signaling cascades evoked by different CD20-targeting compounds vary and remain poorly 
understood, ROS generation has been implicated as an important mechanism of response in 
CD20-targeted cells in different experimental settings (5,6,12,13). 
Cellular senescence is a stress-responsive and ROS-inducible terminal arrest program 
that imposes a barrier to oncogenic transformation in preneoplastic lesions (14-17), has been 
observed in tumor specimens obtained from cancer patients after neo-adjuvant 
chemotherapy (18), and improves long-term outcome after anti-cancer chemotherapy in 
preclinical lymphoma models, especially when apoptosis is no longer available (19,20). 
Besides a distinct senescence-associated morphology and an increased activity of β-
galactosidase at an acidic pH (SA-β-gal) (21,22), senescent cells display a senescence-
associated secretory phenotype (SASP), representing a plethora of secreted factors largely 
consisting of cytokines and chemokines participating in the crosstalk between tumor cells, 
the microenvironment and the host immune system (23-25). While immune cells have been 
implicated in the anti-lymphoma cytotoxic activity of Rituximab via ADCC and related 
mechanisms, the spectrum of anti-tumor activities and potential non-cell-autonomous effects 
of this central immunotherapeutic agent have not fully been elucidated. Specifically, we 
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tested here whether CD20-directed immunotherapy with Rituximab drives lymphoma cell 
senescence, possibly associated with a secretory phenotype (SASP), and augments 
chemotherapy-induced senescence when applied in combination regimens. 
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Methods 
 
Cell lines and treatments 
The neoplastic B-lymphoid cell lines EHEB (chronic lymphocytic B-cell leukemia [CLL]) and 
RC-K8 (diffuse large B-cell lymphoma [DLBCL]) were obtained from M. Hummel (Charité) 
and authenticated in April 2013 using a single nucleotide polymorphism (SNP)-based 
multiplex approach (Multiplexion) (26). SNP profiles matched known profiles, or were unique. 
The SD-1 B-lymphoblastoid cell line (derived from a patient with acute lymphoblastic 
leukemia) and new reference stocks (authenticated by short tandem repeat-based methods) 
of EHEB and RC-K8 were obtained from German Collection of Microorganisms and Cell 
Cultures in December 2013. No mycoplasma contamination was detected in our regular tests 
until October 2015. Cells were cultured for a maximum of four weeks after initial thawing in 
RPMI containing 10% fetal bovine serum (FBS) and penicillin/streptomycin (100 Units/ml)and 
treated with Adriamycin, Vincristine (ADR, VCR, both from Sigma, at doses as indicated), or 
a saturating concentration (20 µg/ml) of Rituximab (RTX, Roche). F(ab’)2 fragments of rabbit-
anti-human IgG (Rockland) were added as cross-linker (CL) at 50 µg/ml one hour after RTX 
to mimic clustering of RTX-bound CD20 via Fc receptor-expressing cells in vivo, reportedly 
augmenting signal transduction after ligation of CD20 (8,27). N-acetyl-cysteine (NAC, 2 mM, 
Hexal) was applied one hour prior to RTX or ADR in some experiments (5). In combined 
immunochemotherapeutic approaches, ADR or VCR were added four hours after CL. 
Compound administration, except for ADR and VCR, was repeated after three days, when 
cultures were subjected to a regular medium exchange. Cell culture supernatant was 
collected for cytokine analyses after overnight incubation of 106 viable cells/ml in fresh media 
without FBS. 
 
Generation of EBV-transformed B-lymphoid cells 
Primary human B-cells were obtained from healthy volunteers after informed consent and 
approval by the local ethics committee of the Charité - Universitätsmedizin Berlin (EA 
7 
4/070/11), and infected with Epstein-Barr virus (EBV) supernatants derived from dense 
cultures of B95/8 cells as published (28). Continuously growing cell lines were treated with 
ADR, RTX and CL as described above. 
 
Analysis of cell growth and SA-β-gal activity 
Viability and cell density were assessed by trypan blue dye exclusion. Senescence-
associated β-galactosidase (SA-β-gal) activity was detected as published (22), and quantified 
in more than five randomly selected areas (of > 200 cells each) in cytospin preparations 
derived from at least two biological replications of the respective cells. Representative 
photomicrographs were taken using a CKX41 microscope equipped with a XC30 camera 
(Olympus). 
 
Flow cytometry, cell-cycle profiling detection of cytokines and intracellular reactive oxygen 
species 
Flow cytometric detection of forward and side scatter characteristics as well as CD20 
expression (Beckman Coulter, IM 1451) was conducted on a Becton Dickinson FACS Calibur 
using BD Biosciences CellQuest Pro (version 4.02) and WinMDI (version 2.9) software. Cell-
cycle distribution (Propidium iodide [PI] staining) combined with incorporation of 
bromodeoxyuridine (BrdU) were assessed as previously described (16). Cytokine 
concentrations were quantified using the FlowCytomix human cardiovascular kit (Bender 
MedSystems; BMS811FF) and FlowCytomix Pro software (version 2.2). Intracellular ROS 
levels were visualized with carboxy-2′,7′-dichlorodihydrofluorescein diacetate (carboxy-
H2DCFDA, 20 µM; Invitrogen) following instructions of the manufacturer. 
 
Protein expression analysis by immunoblotting 
Immunoblotting of whole-cell extracts was performed as described previously (29), using 
primary antibodies for p53 (Santa Cruz Biotechnology, sc-126, 1:500 dilution), p53-P-Ser15 
(Cell Signaling Technology, 9284, 1:1000), p21CIP1 (Santa Cruz Biotechnology, sc-397, 
1:200), γ-H2AX (Cell Signaling Technology, 9718, 1:1000), H3K9me3 (Abcam, ab8898, 
1:1000) and α-Tubulin (Sigma-Aldrich, T6199, 1:2000) as a loading control, with horseradish 
peroxidase-conjugated secondary antibodies (GE Healthcare, NA934V and NXA931). 
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Quantitative transcript and gene set enrichment analyses 
Quantitative real-time reverse transcriptase PCR (RQ-PCR) for interleukin (IL)-6 
(Hs99999032_m1) and IL-8 (Hs01567913_g1) mRNA expression were conducted after oligo-
dT-primed cDNA synthesis for 45 cycles in a Step One Plus Real Time PCR system. 
Expression levels were calculated with GAPDH (Hs02758991_g1) as a housekeeping mRNA 
control as previously described (15). Gene Set Enrichment Analysis (GSEA), based on a 
publicly available data set generated from CD19+-selected peripheral blood CLL specimens 
and downloaded from the Gene Expression Omnibus web site (GEO; 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE15490), was performed with GSEA 
software (Version 2.0, Broad Institute, http://www.broad.mit.edu/gsea) (30,31). Gene sets 
were taken without further change from the indicated publication (32) or assembled from 
hallmark publications (‘Senescence-related genes’, Table S1) (23,33-35). 
 
Statistical analyses 
Normalized enrichment scores reflect a statistically significant enrichment for P values < 0.05 
and false discovery rate values < 0.25 (based on the non-parametrical Kolmogorov-Smirnov 
test). Experimental data were evaluated for statistical significance by employing the unpaired 
Student’s t-test (two-tailed) using the Prism 5 for Windows (version 5.01) software package 
(GraphPad Software). “*” indicates statistical significance (with P < 0.05) in all figures. 
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Results and discussion 
 
To determine the ability of RTX to induce cellular senescence, we analyzed the long-term 
responses of CD20-positive human B-cell lymphoma lines EHEB, RC-K8 and SD-1, which 
displayed typical features of cellular senescence following treatment with the DNA-damaging 
agent Adriamycin (ADR, Figure 1A,B), to RTX with and without addition of a cross-linking 
F(ab’)2 fragment (CL; hereafter referred to as RTXCL). Unlike the growth kinetics observed in 
control settings, cell numbers remained virtually constant in ADR-treated samples, and 
increased much less upon single-agent exposure to RTXCL (Figure 1A). Because RTXCL 
treatment only modestly reduced cellular long-term viability (Figure S1), the RTXCL-related 
marked suppression of cell growth cannot simply be explained by increased cell death. 
Importantly, senescence-reminiscent morphological and flow cytometric changes – enlarged 
cells with a vacuole-rich cytoplasm resulting in increased forward/side scatter values 
(15,18,36) – became detectable in substantial proportions of the cells following ADR or 
RTXCL treatment, and corresponded to significantly increased fractions of SA-β-gal-positive 
cells in comparison to untreated controls (Figure 1B,C), with single-agent RTXCL treatment 
being less efficient regarding its potential to induce senescence when compared to the 
chemotherapeutic agent at its given dose (Figure 1A-C). Hence, we provide here first-time 
evidence, based on a variety of parameters, that RTX treatment evokes a senescent 
phenotype in lymphoma cells. Consistent with this, a substantial reduction of DNA synthesis 
(i.e. BrdU-positive S-phase of the cell-cycle) could be detected in EHEB cells, in which the 
majority of cells displayed features of senescence after RTXCL treatment (P < 0.0001). In line 
with previous characterizations of senescent cell populations, all cell lines exhibited a 
significant accumulation of cells in BrdU-negative S-phase following RTXCL exposure 
(P = 0.0009 for EHEB, P = 0.0018 for RC-K8, and P < 0.0001 for SD-1 cells; Figure 1D and 
Table S1) (37). 
Since many anti-lymphoma treatment protocols, especially against aggressive B-cell 
lymphomas, contain RTX in a combined immunochemotherapy regimen with conventional 
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chemotherapeutic agents such as the topoisomerase poison ADR or the antimicrotubule 
agent Vincristine (VCR) (1), another component of the CHOP regimen, we next analyzed the 
effects of an ADR/RTXCL combination treatment on RC-K8 and SD-1 cells. Addition of RTXCL 
led to a significant increase of the relatively low fractions of senescent cells that were 
detectable in response to a reduced dose of ADR (5 ng/ml in RC-K8, hereafter referred to as 
“ADR 5”, and 2 ng/ml in SD-1 [“ADR 2”], i.e. about half of the initial dose applied; Figure 2A, 
cf. to Figure 1). Accordingly, S-phase-reflecting DNA synthesis, analyzed in viable cells only, 
was profoundly decreased in two-compound-exposed RC-K8 and SD-1 cells when compared 
to single-agent treatments (P < 0.0001 for RC-K8, and P = 0.0117 for SD-1 cells; Figure 2B 
and Table S1). Moreover, fractions of cells in BrdU-negative S-phase, as documented before 
for RTXCL single-agent settings (cf. Figure 1D), were, paralleling the increase of SA-β-gal-
positive cells, significantly expanded (P = 0.0001 for RC-K8, and P < 0.0001 for SD-1 cells). 
Of note, ADR treatment did not induce increased membrane expression of the RTX target 
CD20 (Figure S2A), thereby excluding enhanced antibody efficacy via elevated receptor 
quantities. Therefore, we hypothesized that the high fractions of senescent cells only 
achieved after co-exposure to both RTXCL and ADR may be a result of antibody-mediated 
sensitization towards senescence induction by the DNA-damaging chemotherapeutic agent 
ADR. 
Thus, we next addressed potential amplifier effects of the co-therapeutic schedule on 
senescence-related signaling programs, the secretory phenotype and the DNA damage 
response (DDR) cascade in RC-K8 cells. Consistent with the dose-dependent fractions of 
senescent cells generated in response to ADR, we also found interleukin (IL)-6 and IL-8, two 
major components of the SASP (23,25), at much higher concentrations in the culture 
supernatant of RC-K8 cells exposed to 10 ng/ml instead of 5 ng/ml of ADR (Figure 2C). 
Again, the addition of RTXCL resulted in further, significant induction of IL-6 and IL-8 with 
ADR at both concentrations tested, while RTXCL alone produced only marginal effects 
regarding the expression of these cytokines and their release (Figures 2C,D, and S2B). 
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As persistent activation of the DDR signaling cascade is often considered a prerequisite 
for induction and maintenance of cellular senescence as well as for the SASP (14,23,37,38), 
we analyzed critical DDR components at the time of manifest senescence (Figure 2E) in the 
DLBCL cells. While single-agent RTXCL had little impact on DDR signaling, co-treatment with 
RTXCL strongly enhanced the protein levels of the serine 139-phosphorylated histone variant 
H2A.X (a.k.a. γ-H2AX), a marker related to DNA strand breaks, even further when compared 
to ADR-only settings. Underscoring our hypothesis that RTX may exert its pro-senescent 
potential via sensitization to ADR-induced DDR signaling, we found the serine 15-phospho-
activated tumor suppressor p53 (p53-P-S15) as another DDR signaling component, together 
with stabilization of total p53 protein and increased protein levels of the senescence-
implicated cell-cycle regulator and transcriptional p53 target p21CIP1 to be induced in ADR-
senescent, but even more in RTXCL/ADR-co-treated cells. Consistent with a sustained and 
particularly active DDR cascade promoting senescence in response to the combined 
treatment, we detected trimethylated lysine 9 of histone H3 (H3K9me3), the transcriptionally 
repressive chromatin modification that has been mechanistically linked to the selective 
silencing of E2F-dependent S-phase genes in senescence (15,16,39), at particularly high 
levels in ADR-treated cells co-exposed to RTXCL (Figure 2E). Of note, the microtubule-
disrupting anti-lymphoma agent VCR, which does not primarily target DNA replication but 
induces p53 phosphorylation and interferes with DNA repair in cancer cells as well, also 
showed, like ADR, albeit less pronounced, significant collaborative senescence-inducing 
effects when RTXCL was added (Figure 2F; cf. Figure 2A) (40,41). Taken together, Rituximab 
and conventional chemotherapy cooperatively induce senescence via sensitization to pro-
senescent DDR signaling. 
Elevation of intracellular ROS levels has been identified as a response to RTX in other 
settings (5,12), promotes DNA damage (29), and is a known trigger of cellular senescence 
as well (17,38). In line with this, we detected elevated ROS levels shortly after RTXCL 
treatment (Figure 3A), and observed a complete loss of RTX-mediated senescence in the 
presence of the ROS scavenger N-acetylcysteine (NAC; Figure 3B,C; cf. Figure 1) in RC-K8 
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cells. Of note, NAC, at this dose, did not abrogate target cell binding of RTX (Figure S3A,B), 
and only moderately affected senescence entry in response to ADR (Figure 3C). These 
findings pinpoint ROS as the critical mediator of RTX-, but to a much lesser extent of ADR-
induced senescence, thereby contrasting distinct RTX- vs. ADR-triggered senescence 
initiator pathways, which synergistically converge into p53-governed senescence effector 
signaling. 
Although apoptosis- and senescence-regulating pathways are often defective in culture-
adapted cancer cell lines (42), we were able to detect therapy-induced senescence after both 
ADR and RTXCL in established lymphoma cell lines of B-cell origin. In order to validate our 
cell line model-based findings in primary human B-cells and primary human B-cell 
malignancies, we applied Rituximab to Epstein-Barr virus (EBV)-transformed, CD20-positive 
(data not shown) B-lymphoblastoid cells (28), and observed increased SA-β-gal reactivity in 
response to RTXCL treatment as well as augmented senescence levels in comparison to 
single-agent ADR after combined immunochemotherapy (Figure 4A,B). Hence, the pro-
senescent activity of RTX as a monotherapy and even further in a chemo-co-therapeutic 
setting can be demonstrated in primary, transformed human B-cells as well. 
Finally, to estimate the clinical contribution of senescence as an effector mechanism of an 
RTX-containing chemotherapeutic regimen, we aimed at testing senescence-related gene 
sets in transcriptome data obtained from responding vs. non-responding patients diagnosed 
with B-cell chronic lymphocytic leukemia (B-CLL). Specifically, we analyzed gene sets that 
had previously been identified as “fingerprints” of (replicative) senescence in human cells 
(32), or were assembled as “senescence-related” from pivotal publications (23,33-35) 
(Table S2), regarding their potential enrichment in a sequential gene expression data set 
derived from B-CLL patients who had just received the first cycle of standard 
immunochemotherapy with the anti-CD20 antibody RTX, and the DNA-damaging 
conventional chemotherapeutic agents Fludarabine and Cyclophosphamide (30). Strikingly, 
the sample set obtained from subsequently responding patients (i.e. achieving partial or 
complete remissions after three months of treatment) displayed an enrichment in several 
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senescence-associated gene sets already one day after treatment, while no concordant 
enrichment was seen in non-responders (i.e. those patients presenting with stable or 
progressive disease at three months; Table 1). Taken together, these results underscore a 
beneficial role for Rituximab-induced senescence regarding the clinical outcome of patients 
with a CD20-positive B-cell malignancy. 
In essence, the evidence presented here marks cellular senescence as an additional 
effector program by which RTX exerts its anti-lymphoma potential, and argues for a ROS-
mediated mechanism as the underlying mode of RTX-mediated senescence induction. When 
co-administered with classic DNA-damaging drugs such as ADR, RTX sensitizes to 
chemotherapy-induced senescence and potentiates the extent of senescence-related 
chemokine and cytokine secretion (16,33,34). Moreover, SASP reinforces senescence, and 
may further add to treatment efficacy via modulation of RTX-engaged immune cell action 
(33,34). Possibly operating similarly, the epidermal growth factor receptor-blocking antibody 
Cetuximab reportedly sensitizes lung cancer cells to irradiation-induced senescence (while 
not producing senescence on its own) (43), and recently, increased SA-β-gal activity became 
detectable after application of Obinutuzumab, another CD20-directed antibody, in a cell line-
based model of follicular lymphoma (44). Importantly, RTX-induced senescence does not 
seem to primarily damage DNA, as other non-genotoxic stimuli have been shown to produce 
cellular senescence (16,20,45). However, RTX-induced and ROS-promoted sensitization to a 
DDR that is mounted by conventional chemotherapeutic agents provides an explanation for 
the senescence-facilitating effect of this CD20-directed treatment, and may in part account 
for the clinical benefit of therapeutic regimens that include RTX. Moreover, since senescent 
tumor cells were shown to attract immune cells to the tumor site (24,46), 
immunochemotherapy-induced senescence with its strongly elevated SASP could even 
further improve immune clearance of lymphoma cells in vivo. Further molecular elucidation of 
the complex interplay between conventional anti-cancer agents, Rituximab and, alternatively, 
other CD20-directed compounds with respect to senescence induction will open the clinical 
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perspective of specifically engaging the senescence program to further improve therapeutic 
outcome of lymphoma patients. 
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Table 1. Predictive role of senescence-associated gene sets in patients diagnosed 
with chronic lymphocytic leukemia (CLL) undergoing RTX-based 
immunochemotherapy. 
 
Gene signature NR R 
Down in senescent fibroblasts 1.814 -1.769* 
Up in senescent fibroblasts -0.892 0.681 
Down in senescent MEC 1.208 0.880 
Up in senescent MEC 0.665 1.495* 
Senescence-related genes -0.893 1.514* 
 
Tabular representation of nominal enrichment scores of gene sets comparing expression 
levels in tumor samples obtained 1 day post-treatment to specimens collected immediately 
before initiation of therapy in non-responding (NR, n = 5, left panel) and responding (R, n = 5, 
right panel) CLL patients undergoing immunochemotherapy with RTX, Fludarabine and 
Cyclophosphamide (30). ‘*’ indicates significant (nominal P-value < 0.05) concordant 
regulation of the respective gene set. Gene sets reflect genes that had previously been found 
as up- or down-regulated in different senescent human cells (32), or were assembled as 
“senescence-related” in an unbiased fashion from pivotal publications (23,33-35). 
 
 
Figure legends 
 
Figure 1. Human lymphoma cells enter senescence in response to Rituximab-based 
immunotherapy. (A) Cell numbers of viable EHEB, RC-K8 and SD-1 cells at the indicated 
time-points relative to start of treatment with cross-linker (CL), Rituximab (RTX), combined 
RTX and CL (RTXCL), Adriamycin (ADR; 10 ng/ml for EHEB and RC-K8, 5 ng/ml for SD-1), or 
left untreated (ut). Means of at least two independent experiments each performed in 
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triplicates are shown; arrow bars denote standard deviations. (B) Representative 
photomicrographs of cytospin preparations stained for senescence-associated-β-
galactosidase (SA-β-gal) activity after six days. Scale bars indicated in controls correspond to 
50 µm (left panel) and 20 µm (right upper panel) in all settings, numbers reflect mean 
percentages of SA-β-gal positive cells ± standard deviations. Right lower panel: Flow 
cytometric analyses (density plots) of forward (FSC) and side (SSC) scatter characteristics of 
the corresponding cell populations after six days. (C) SA-β-gal activity in all scenarios tested. 
(D) Representative images of cell-cycle distribution as assessed by quantitative Propidium 
iodide (PI) staining (depicted on the X-axis) combined with incorporation of 
bromodeoxyuridine (BrdU, y-axis) 6 days after treatment as indicated. “*” denotes statistical 
significance of differences (P < 0.05) in (C) and (D). 
 
Figure 2. Rituximab treatment augments chemotherapy-induced senescence via 
enhanced DNA damage signaling. (A) Representative SA-β-gal stainings, quantifications of 
SA-β-gal activity (generated in more than five randomly selected areas of > 200 cells each 
derived from at least two biological replications) and FSC/SSC density plots of RC-K8 and 
SD-1 cells six days after start of treatment (as in Figure 1B) with ADR concentrations that 
were incapable of inducing maximum senescence levels (5 ng/ml in RC-K8 cells [“ADR 5”] 
and 2 ng/ml in SD-1 [“ADR 2”]) as single agent or combined with RTXCL. See Figure 1 for 
corresponding controls. (B) Comparison of BrdU/PI profiles of cells treated as in (A). (C) 
Representative flow cytometric multiplex bead-based fluorescence profiles of the indicated 
peptides in cell culture supernatants collected overnight from RC-K8 cells that had been 
treated as indicated for six days. Cytokine concentrations are plotted on the x-axis 
(logarithmic scale, log); bead populations corresponding to individual peptides are 
discriminated via peptide-specific fluorescence levels on the y-axis. Vertical marks indicate 
the positions of bead clouds corresponding to two major SASP cytokines, i.e. interleukin (IL)-
6 (red) and IL-8 (blue) compared to untreated controls (hatched lines) for different ADR 
concentrations without RTXCL (upper panel) or with RTXCL (lower panel). IL-6 and IL-8 
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concentrations are indicated in the lower right corner of each panel (pg/ml, mean values ± 
standard deviations from two independent experiments, each conducted in triplicate). No 
profoundly increased concentrations were detected for two other SASP factors tested (47), 
the tissue-type plasminogen activator (t-PA) and the membrane cofactor protein-1 (MCP-1). 
The soluble CD40 ligand (sCD40L) has to our knowledge not been described as a 
component of the SASP (23). (D) Quantitative RT-PCR analyses of IL-6 (left) and IL-8 (right) 
mRNA expression levels relative to untreated controls in RC-K8 cells exposed to the 
indicated treatments for six days. Arrow bars indicate standard deviations of two independent 
experiments performed in triplicates. (E) Western blot analyses of the indicated (phospho-) 
proteins in RC-K8 cells exposed for six days to ADR (5 or 10 ng/ml) and/or RTXCL or left 
untreated. α-Tubulin serves as loading control. (F) Fractions of SA-β-gal-positive cells by 
Vincristine only (black bars, 2.5 ng/ml for RC-K8 and 0.5 ng/ml for SD-1) and with additional 
RTXCL exposure (grey bars) in RC-K8 and SD-1 cells. 
 
Figure 3. Rituximab-mediated senescence depends on ROS signaling. (A) Intracellular 
ROS levels (logarithmic scale) by carboxy-2′,7′-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA)-based flow cytometry after RTXCL as compared to the untreated (ut) 
condition. Time-points at which detected differences were most pronounced (1 day for EHEB 
and SD-1, 4 hours for RC-K8) are shown. (B) Growth characteristics, morphology and SA-β-
gal activity of RTXCL-treated RC-K8 cells (as in Figure 1B) after pre-incubation with the ROS 
scavenger NAC. Note the increased number of cells in the RTXCL setting despite impaired 
growth of controls with NAC pre-treatment (cf. Figure 1A). Again, values derived from two 
experiments, each conducted in three replicates, are shown. (C) Comparison of SA-β-gal 
reactivity (values generated as described in figure 1) in RC-K8 cells exposed to RTXCL or 
ADR (10 ng/ml) in the presence or absence of NAC. 
 
Figure 4. RTX-induced senescence in primary human Epstein-Barr virus (EBV)-
transformed B-lymphoblastoid cells. (A) Representative visualizations of SA-β-gal 
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detection and FSC/SSC plots in four individual EBV-transformed B-lymphoblastoid cell 
preparations after six days of treatments as indicated. Numbers reflect mean percentages of 
SA-β-gal positive cells ± standard deviations; scale bars in the control correspond to 50 µm 
(left panel) and 20 µm (right upper panel) in all settings. (B) Comparison of senescence 
levels achieved by single-agent ADR treatment (5 ng/ml) and additional RTXCL as in 
Figure 2A (n = 4). 
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